Article
The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21
2024-08-19
Abstract excerpt
Obesity is a debilitating disease with increasing worldwide prevalence. Despite its high prevalence, specific pharmacologic intervention for obesity is challenging. Here, we report that halofuginone, an FDA-approved anti-scleroderma and anti-protozoal drug, is a promising anti-obesity agent in rodent models. Halofuginone suppressed food intake, increased energy expenditure, and resulted in weight loss in preclinic...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7b72d00b-67ce-53d2-892e-2165b41368d1
- DOI
- 10.1101/2024.08.18.608423
